Treating Life-Threatening Bleedings

Development of Recombinant Coagulation Factor Viia
Erscheinungsjahr 2017
ISBN: 978-0-12-812439-0
Verlag: Elsevier Science

Buch, Englisch, 214 Seiten, Format (B × H): 150 mm x 228 mm, Gewicht: 336 g

Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work.

The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences.

Zielgruppe

Residents, fellows and professionals in hematology, pathology, surgery, internal/hospital medicine, public health

Autoren/Hrsg.

Hedner, Ulla

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Chirurgie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Innere Medizin
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Public Health, Gesundheitsmanagement, Gesundheitsökonomie, Gesundheitspolitik
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pathologie, Cytopathologie, Histopathologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Hämatologie, Transfusionsmedizin

Inhaltsverzeichnis

1. Classical Bleeding Disease (Hemophilia)2. My Encounter With Hemophilia (1959-82)3. The First Years at Novo Nordisk4. The Development of Recombinant FVIIa (rFVIIa) (1985-88)5. The Further Use and Development of rFVIIa (1989-96)6. Legal Issues Regarding the Use of rFVIIa in Hemophilia Patients With Inhibitors7. Treatment With rFVIIa in Malmö (1996-99)8. The Launching and Uses of rFVIIa9. Mechanism of Action and Dosage10. The Continued Development of rFVIIa During the 2000s11. Safety and Health Economy of rFVIIa12. Three Different Descriptions of How rFVIIa Was Developed13. Some Final Remarks

Über Autor(innen)

Hedner, Ulla
Dr. Hedner has been active in the field of Thrombosis and Haemostasis for more than 40 years and initiated the idea to use FVIIa as a hemostatic drug when working as a clinician at the University Hospital of Malmö, Lund University, Sweden, in the 1970s. Later, she led the development of recombinant FVIIa when being part of the Department of Research & Development at the Danish pharmaceutical company Novo Nordisk A/S, Bagsværd, Denmark.
Dr. Hedner was a physician at the Department of Bleeding Disorders including a Haemophilia Comprehensive Clinic, Malmö University Hospital, University of Lund, Sweden from 1972-1983. Her research and teaching experience was at the Medical Faculty of Lund University, Sweden and Professor in Clinical Coagulation Research at the University of Gothenburg and at the University of Lund.